UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

~~November~~April 1128, ~~2002~~2003 (Date of earliest event reported)

SANGSTAT MEDICAL CORPORATION (~~Date~~Exact name of ~~earliest~~Registrant ~~event~~as ~~reported~~specified in its charter)

Delaware 0-22890 94-3076-069
(State of incorporation or organization) (Commission File No.) (IRS Employer Identification No.)

SANGSTAT MEDICAL CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware	0-22890	94-3076-069
(State of incorporation or organization)	(Commission File No.)	(IRS Employer Identification No.)
6300 Dumbarton Circle Fremont, CA 94555
(Address of principal executive offices)
(510) 789-4300
(Registrant’s telephone number, including area code)

6300 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)

~~Item~~(510) 5.789-4300 (Registrant’s ~~Other~~telephone ~~Events.~~number, including area code)

OnItem ~~November 11, 2002, SangStat Medical Corporation (the “Company”) issued a press release announcing that it had entered into a strategic collaboration with Therapeutic Human Polyclonals, Inc~~5. ~~(“THP”)~~Other to develop and commercialize humanized polyclonal antibodies. In addition, the Company announced that Roland Buelow, Ph.D., Senior Vice President of Discovery Research, resigned from the Company to assume the position as Chief Scientific Officer for THP. During a transition period, Dr. Buelow will continue to work part-time for the Company. Timothy Fong, Ph.D., currently the Company’s Vice President for Discovery Research, will now take the leading role in directing the activities of the Company’s discovery research division.Events

A On ~~copy~~April of28, 2003, SangStat Medical Corporation issued the ~~press~~attached ~~release~~press release announcing ~~these~~its ~~events~~sales isand ~~filed~~earnings asfor ~~exhibit~~the ~~99.1~~period toended ~~this~~March ~~report~~31, 2003.

Item 7. Exhibits.

(a) Not applicable. (b) Not applicable. (c) Not applicable.

~~(b) Not applicable~~ Exhibit No. Description

~~(c) Exhibits~~ 99.1 Press release dated April 28, 2003.

Exhibit No.		Description
99.1		Press release dated November 11, 2002

Item 9. Regulation FD Disclosure

2 Incorporated by reference is a press release issued by the Registrant on April 28, 2003, regarding earnings for the first quarter 2003, attached as Exhibit 99.1. This information is being furnished pursuant to Item 12 – Results of Operations and Financial Condition, of Form 8-K and is being presented under Item 9 of Form 8-K in accordance with interim guidance issued by the Securities and Exchange Commission in Release Nos. 33-8216 and 34-47583. This information is not deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.

~~SIGNATURE~~2

~~Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURE

	SANGSTAT MEDICAL CORPORATION
	By:	/s/ Stephen G. Dance
		Stephen G. Dance
		Senior Vice President, Finance
Date: November 14, 2002

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3 SANGSTAT MEDICAL CORPORATION By: /s/ Stephen G. Dance Stephen G. Dance Date: April 28, 2003 Chief Financial Officer

~~EXHIBIT INDEX~~3

Exhibit No.		Description
99.1		Press release dated November 11, 2002

EXHIBIT INDEX

4 Exhibit No. Description

99.1 Press release dated April 28, 2003.

Filing Compare · SANGSTAT MEDICAL CORP